Table 2

Regression model for analysing time to first clinical relapse

Time to first relapseHR95% CIP value
Sex (male (57) vs female (113; ref.))0.7070.415 to 1.2060.203
Age (<34 years (84; ref.) vs ≥34 years (86))1.2010.729 to 1.9810.472
Annualised relapse rate at baseline1.4601.098 to 1.940 0.009
Baseline-EDSS1.0040.805 to 1.2520.973
Disease duration since onset (yrs)0.9450.891 to 1.0030.062
Last previous DMT (naïve=ref. (35)) basic (52)0.9300.410 to 2.1100.983
NTZs (21)2.7321.138 to 6.560 0.025
NTZa (29)3.8881.375 to 10.990 0.010
FTY (33)5.4202.520 to 11.660 <0.001
  • Results from our Cox proportional hazard model using an enter method to integrate all the covariates in the final analysis. For analysis of age as a covariate, we split our group according to the median. Reference categories are indicated for categorical covariates. Numbers in brackets in the first column indicate sample numbers for the respective covariate.

  • Bold values indicate p-values below 0.05

  • DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; FTY, fingolimod; NTZa, natalizumab (previously active); NTZs, natalizumab (active subgroup).